TNF and human African trypanosomiasis: Since TNF-alpha is one of the causes of cachexia (wasting) associated with African sleeping sickness (51) and is involved in immunosuppression in trypanosome infected animals (52), the data suggest that BMAP-18 is an excellent candidate for testing in vivo as a therapeutic that would directly kill trypanosomes while helping to maintain the overall health of the infected host.